Download
s00432-020-03327-2.pdf 926,75KB
WeightNameValue
1000 Titel
  • Results of a randomized trial of treatment modalities in patients with low or early-intermediate risk prostate cancer (PREFERE trial)
1000 Autor/in
  1. Wiegel, Thomas |
  2. Albers, Peter |
  3. Bartkowiak, Detlef |
  4. Bussar-Maatz, Roswitha |
  5. Härter, Martin |
  6. Kristiansen, Glen |
  7. Martus, Peter |
  8. Wellek, Stefan |
  9. Schmidberger, Heinz |
  10. Grozinger, Klaus |
  11. Renner, Peter |
  12. Schneider, Fried |
  13. Burmester, Martin |
  14. Stöckle, Michael |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-09-04
1000 Erschienen in
1000 Quellenangabe
  • 147(1):235-242
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1007/s00432-020-03327-2 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7810635/ |
1000 Publikationsstatus
1000 Begutachtungsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Purpose: The optimal treatment for patients with low to early-intermediate risk prostate cancer (PCa) remains to be defined. The randomized PREFERE trial (DRKS00004405) aimed to assess noninferiority of active surveillance (AS), external-beam radiotherapy (EBRT), or brachytherapy by permanent seed implantation (PSI) vs. radical prostatectomy (RP) for these patients. Methods: PREFERE was planned to enroll 7600 patients. The primary endpoint was disease specific survival. Patients with PCa stage <= cT2a, cN0/X, M0, PSA <= 10 ng/ml and Gleason-Score <= 3 + 4 at reference pathology were eligible. Patients were allowed to exclude one or two of the four modalities, which yielded eleven combinations for randomization. Sixty-nine German study centers were engaged in PREFERE. Results: Of 2251 patients prescreened between 2012 and 2016, 459 agreed to participate in PREFERE. Due to this poor accrual, the trial was stopped. In 345 patients reference pathology confirmed inclusion criteria. Sixty-nine men were assigned to RP, 53 to EBRT, 93 to PSI, and 130 to AS. Forty patients changed treatment shortly after randomization, 21 to AS. Forty-eight AS patients with follow-up received radical treatment. Median follow-up was 19 months. Five patients died, none due to PCa; 8 had biochemical progression after radical therapy. Treatment-related acute grade 3 toxicity was reported in 3 RP patients and 2 PSI patients. Conclusions: In this prematurely closed trial, we observed an unexpected high rate of termination of AS and an increased toxicity related to PSI. Patients hesitated to be randomized in a multi-arm trial. The optimal treatment of low and early-intermediate risk PCa remains unclear.
1000 Sacherschließung
lokal Prostatectomy
lokal Adolescent [MeSH]
lokal Disease Progression [MeSH]
lokal Follow-Up Studies [MeSH]
lokal Permanent seed implantation
lokal Aged [MeSH]
lokal Adult [MeSH]
lokal Original Article – Clinical Oncology
lokal Humans [MeSH]
lokal Randomized clinical trial
lokal Active surveillance
lokal Prostatic Neoplasms/pathology [MeSH]
lokal External beam radiotherapy
lokal Middle Aged [MeSH]
lokal Brachytherapy/methods [MeSH]
lokal Male [MeSH]
lokal Prognosis [MeSH]
lokal Watchful Waiting/methods [MeSH]
lokal Young Adult [MeSH]
lokal Prostatic Neoplasms/therapy [MeSH]
lokal Combined Modality Therapy [MeSH]
lokal Prostatectomy/methods [MeSH]
lokal Prostate cancer
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0003-1363-1410|https://frl.publisso.de/adhoc/uri/QWxiZXJzLCBQZXRlcg==|https://frl.publisso.de/adhoc/uri/QmFydGtvd2lhaywgRGV0bGVm|https://frl.publisso.de/adhoc/uri/QnVzc2FyLU1hYXR6LCBSb3N3aXRoYQ==|https://frl.publisso.de/adhoc/uri/SMOkcnRlciwgTWFydGlu|https://frl.publisso.de/adhoc/uri/S3Jpc3RpYW5zZW4sIEdsZW4=|https://frl.publisso.de/adhoc/uri/TWFydHVzLCBQZXRlcg==|https://frl.publisso.de/adhoc/uri/V2VsbGVrLCBTdGVmYW4=|https://frl.publisso.de/adhoc/uri/U2NobWlkYmVyZ2VyLCBIZWlueg==|https://frl.publisso.de/adhoc/uri/R3JvemluZ2VyLCBLbGF1cw==|https://frl.publisso.de/adhoc/uri/UmVubmVyLCBQZXRlcg==|https://frl.publisso.de/adhoc/uri/U2NobmVpZGVyLCBGcmllZA==|https://frl.publisso.de/adhoc/uri/QnVybWVzdGVyLCBNYXJ0aW4=|https://frl.publisso.de/adhoc/uri/U3TDtmNrbGUsIE1pY2hhZWw=
1000 Hinweis
  • DeepGreen-ID: 43747c26506b47f7be8285c4bd170573 ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6469360.rdf
1000 Erstellt am 2023-11-17T22:12:13.113+0100
1000 Erstellt von 322
1000 beschreibt frl:6469360
1000 Zuletzt bearbeitet Fri Dec 01 09:41:45 CET 2023
1000 Objekt bearb. Fri Dec 01 09:41:45 CET 2023
1000 Vgl. frl:6469360
1000 Oai Id
  1. oai:frl.publisso.de:frl:6469360 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source